Please login to the form below

Not currently logged in
Email:
Password:

cHL

This page shows the latest cHL news and features for those working in and with pharma, biotech and healthcare.

Keytruda doubles five-year survival rate in NSCLC

Keytruda doubles five-year survival rate in NSCLC

Since then, the immunotherapy has added an array of indications to its arsenal, including approvals for the treatment of head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), cervical cancer,

Latest news

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
fox&cat

up to your ears in it? some pressure is helpful but too much of the wrong sort quickly takes its...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....